Genmab A/S (NASDAQ:GMAB) said three positive Phase III readouts across lymphoma, ovarian cancer and head and neck cancer could support multiple potential product launches beginning in 2027, as the company seeks to increase growth from medicines it owns or co-develops. Chief Executive Officer Jan van de Winkel said the company reported positive late-stage results during […]